Latest Retinitis pigmentosa Stories
April Flowers for redOrbit.com - Your Universe Online Columbia University ophthalmologists and stem cell researchers have developed an experimental treatment for blindness using the patient's skin cells, which has improved the vision of blind mice in testing. The findings of this research, published online in the journal Molecular Medicine, suggest that induced pluripotent stem cells (iPS) could soon be used to improve vision in people with macular degeneration and other eye retina...
REUTLINGEN, Germany, Sept. 27, 2012 /PRNewswire/ -- Retina Implant AG, the leading developer of subretinal implants for patients blinded by retinitis pigmentosa (RP), announced that its scientific advisory board has been debriefed on the latest results in the Company's second human clinical trial. On September 23 Lead Investigator Eberhart Zrenner, M.D., professor of Ophthalmology and founding director of the Institute for Ophthalmic Research at the Centre for Ophthalmology of the...
Connie K. Ho for redOrbit.com – Your Universe Online A new study by German researchers found that a light-sensitive element that was mixed with the anesthetic propofol was able to be managed by light and the mixture could possibly be used to treat particular eye disorders. To begin, the scientists believe that inhibitory neurotransmitters can limit the activity of neurons and this reduction effect acts as the foundation for different anesthetics. In particular, propofol can work with...
MILAN, Italy, Sept. 5, 2012 /PRNewswire/ -- Retina Implant AG, the leading developer of subretinal implants for patients blinded by retinitis pigmentosa (RP), today announced that results from the Company's second human clinical trial will be presented at the 12(th) EURETINA Congress, in Milan, 6-9 September. On Friday, 7 September at 16:45 CEST Professor Eberhart Zrenner, director and chairman of the Institute for Ophthalmic Research at the Centre for Ophthalmology of the...
MILAN, Sept. 5, 2012 /PRNewswire/ -- Okuvision GmbH, the leading developer of transcorneal electrical stimulation (TES) therapy for patients with early-to mid-stage retinitis pigmentosa (RP) today announced that results from the Company's human clinical trial will be shared at the 12(th) EURETINA Congress, in Milan, 6-9 September. The abstract titled "Effects of Transcorneal Electrical Stimulation in Patients with Retinitis Pigmentosa" will be presented by Dr. Tobias Roeck from the...
Lee Rannals for redOrbit.com – Your Universe Online An Australian woman has partially regained her sight thanks to a prototype bionic eye scientists have developed. Dianne Ashworth had severe vision loss due to retinitis pigmentosa, but thanks to a bionic eye transplant in May at the Royal Victorian Eye and Ear Hospital, she was able to see different shapes. "All of a sudden I could see a little flash ... it was amazing," Ashworth, who is 54 years old, said in a statement. "Every...
Research conducted at the Angiogenesis Laboratory at Massachusetts Eye and Ear Infirmary, has for the first time, identified the mode of death of cone photoreceptor cells in an animal model of retinitis pigmentosa (RP). This groundbreaking study, led by Demetrios G. Vavvas, M.D., Ph.D., and including Joan W. Miller, M.D., Mass. Eye and Ear/Mass General Hospital Chief of Ophthalmology and Chair of Ophthalmology at Harvard Medical School, has further identified the receptor interacting protein...
Dr.Burton Feinerman of StemCell RegenMed announces the recruitment of patients diagnosed with Retinitis Pigmentosa, Age related Macular Degeneration and Stargardt Macular Degeneration. Patients with these diseases face the development of blindness at varying age levels. Aventura (N. Miami), Florida (PRWEB) July 25, 2012 Dr.Burton Feinerman of StemCell RegenMed announces the recruitment of patients diagnosed with Retinitis Pigmentosa, Age related Macular Degeneration and Stargardt Macular...
OXFORD, England, July 23, 2012 /PRNewswire/ -- -- Award of US$125,000 will support a second clinical site in Paris, France -- Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), the leading gene-based biopharmaceutical company, today announces that the US non-profit organisation, the Foundation Fighting Blindness (FFB), has granted an award of US$125,000 to the Company via its translational research arm, the Foundation Fighting Blindness Clinical...
HUNTINGTON’S DISEASE, for the FIRST time in history was treated in March 2012 by Dr.’s Feinerman and Paino in our state of the art clinic in Lima, Peru. Two sisters with this debilitating disease will be followed over the next year after a very successful treatment. You can follow the progress and see other testimonials on our website, http://www.stemcellregenmed.com Aventura, North Miami, Florida (PRWEB) June 11, 2012 In a time of such an amazing biotechnology medical era in which...
